Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

TIMENTIN

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

Standard Dose
EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TIMENTIN is listed in Drugs@FDA under application 050590 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM Form and strength INJECTABLE;INJECTION - EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2014-06-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview TIMENTIN is listed in Drugs@FDA under application 050590 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM Form and strength INJECTABLE;INJECTION - EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2014-06-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.